Evomela

Patient Information

Learn about EVOMELA (melphalan) for Injection

What is EVOMELA?

EVOMELA is a prescription medicine also known as melphalan used in people with a type of cancer called multiple myeloma.

EVOMELA is used as a “conditioning treatment” (doctors sometimes call this myeloablation) for people who have multiple myeloma prior to a procedure called stem cell transplantation.

EVOMELA is also used as a part of care to support symptom relief (palliative treatment) in people with multiple myeloma who cannot take melphalan by mouth.

It is not known if EVOMELA is safe and effective in children.

Understanding the Language

Definition: Conditioning Treatment
The treatments (or regimen) used to prepare a patient for stem cell transplantation. Conditioning helps make room in the patient’s bone marrow for new blood stem cells to grow, helps prevent the patient's body from rejecting the transplanted cells, and may help reduce cancer cells (in this case, multiple myeloma cells) that are in the body.2

Definition: Stem cell transplantation
A procedure in which a person receives blood stem cells, which make any type of blood cell2

EVOMELA is the only formulation of melphalan approved by the U.S. Food and Drug Administration for high-dose conditioning treatment.1,3

Please talk with your healthcare professionals to learn more about EVOMELA and for more information about conditioning treatment before stem cell transplantation.

Call your healthcare professional for medical advice about side effects. You are encouraged to report negative side effects to the FDA. Visit www.FDA.gov/medwatch or call 1-800-FDA-1088.

PATIENT INFORMATION EVOMELA PRESCRIBING INFORMATION

References

  1. EVOMELA [prescribing information]. Irvine, CA: Spectrum Pharmaceuticals; March 2016.
  2. American Cancer Society. Stem Cell Transplant for Cancer. http://www.cancer.org/acs/groups/cid/documents/webcontent/003215-pdf.pdf. Accessed June 17, 2016.
  3. Melphalan Hydrochloride for Injection [prescribing information]. Mylan Institutional LLC; August 2012.